Systematic review and meta-analysis of biopsy-guided versus clinically guided withdrawal in autoimmune hepatitis
Biopsy-guided withdrawal shows no benefit over clinical guidance for autoimmune hepatitis
This systematic review and meta-analysis evaluated relapse rates after treatment withdrawal in patients with autoimmune hepatitis.
A meta-analysis of 518 patients found that biopsy-guided withdrawal did not lower relapse rates compared to clinically guided withdrawal in …
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Research across Hepatitis
Related studies from across the Hepatitis family.
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations
HLA genes shape HIV and hepatitis vaccine responses and drug reactions
This narrative review examines HLA polymorphisms in HIV, hepatitis C, and hepatitis B. The clearest preventive paradigm is HLA-B*57:01-guide…
A review finds that HLA genes strongly influence how people respond to HIV and hepatitis vaccines and how they react to certain medications.
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B
Combination therapies may improve functional cure rates for chronic hepatitis B
This narrative review examines combining pegylated interferon-α with novel immunotherapies (antigen-reduction strategies, therapeutic vaccin…
A review suggests combining pegylated interferon with new immunotherapies could help achieve functional cure in chronic hepatitis B patients…
Chronic HCV infection drives T cell dysfunction, regulatory T cell accumulation, and metabolic defects that persist after viral clearance
Immune defects in hepatitis C may last after the virus is gone
This narrative review examines immune mechanisms in patients with chronic hepatitis C virus infection. The authors describe how prolonged an…
A review explains how chronic hepatitis C causes lasting immune changes that persist even after the virus is cleared, suggesting new treatme…
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds
1 in 6 blood donors in Cameroon carries malaria parasite
A systematic review and meta-analysis of 18 studies (~12,500 donations) found a 16.6% pooled prevalence of Plasmodium spp. in Cameroonian bl…
A review of 18 studies finds 16.6% of blood donations in Cameroon contain Plasmodium, the malaria parasite.
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
Meta-analysis identifies genetic variants linked to HBV susceptibility and HCC risk
Genetic Keys Unlock Why Some Get Liver Cancer From Hepatitis B
This meta-analysis of East Asian cohorts examined genetic variants associated with hepatitis B virus infection and hepatocellular carcinoma …
New research shows specific gene changes help explain why some people get Hepatitis B while others stay healthy.
HEV 239 vaccine induces durable humoral and cellular immunity in Bangladeshi women
Hepatitis E vaccine shows durable immunity in women
This longitudinal cohort study in 1480 women aged 16-39 years in Bangladesh found that HEV 239 (Hecolin) vaccination led to significantly hi…
A hepatitis E vaccine kept women protected for up to 3 years, with stronger immune memory than a comparison group.
Pegylated interferon alpha associated with HBsAg clearance in postpartum women with chronic HBV infection
New treatment clears hepatitis B in 3 out of 10 women after childbirth
This prospective cohort study evaluated 263 postpartum women with chronic hepatitis B virus infection and baseline HBsAg levels ≤3000 IU/mL.
A new treatment clears hepatitis B markers in nearly 30% of women after childbirth, offering fresh hope for a functional cure during a uniqu…
Absence of antiviral therapy and multiple chemotherapeutic agents increase HBV reactivation risk after TACE
No Antiviral Meds Raise Liver Cancer Risks After Chemo
This retrospective cohort study of 168 HBsAg-positive HCC patients undergoing TACE found that absence of prophylactic antiviral therapy (OR …
Many liver cancer patients with hepatitis B face avoidable risks during chemo—because they’re not getting a simple antiviral pill most alrea…
Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.